Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.
Leukemia
; 35(5): 1267-1278, 2021 05.
Article
in En
| MEDLINE
| ID: mdl-33531656
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
B-Lymphocytes
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/
TOR Serine-Threonine Kinases
/
Antineoplastic Agents
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Child
/
Humans
Language:
En
Journal:
Leukemia
Year:
2021
Document type:
Article